Pricing Log in Create free account

Lucid Diagnostics Inc. (LUCD) vs Sera Prognostics, Inc. (SERA)

Lucid Diagnostics Inc. and Sera Prognostics, Inc. are both Medical Devices companies. Lucid Diagnostics Inc. and Sera Prognostics, Inc. are of similar size ($82.1M and $79.3M). Lucid Diagnostics Inc. grew revenue faster over the last twelve months: 24.9% against 1.05%. Lucid Diagnostics Inc. has the higher net margin (−1,193.9% vs −34,866.7%) and the lower return on invested capital (−3,096.5% vs −278.6%). Across the 17 metrics below, Lucid Diagnostics Inc. leads on 9 and Sera Prognostics, Inc. on 8.

Valuation

Metric LUCD SERA Medical Devices median
P/E n/m n/m 25.58
P/S 13.12 1,100.45 2.54
P/B 6.54 2.01 2.48
Price to free cash flow n/m n/m 28.81
EV/EBITDA n/m n/m 11.51
EV/Sales 11.30 641.21 2.72
Earnings yield (120.51%) (32.21%) (12.82%)
Free cash flow yield (66.07%) (27.81%) (8.18%)

Profitability

Metric LUCD SERA Medical Devices median
Gross margin (21.69%) 0.00% 57.76%
Operating margin (930.84%) (38,755.21%) (15.07%)
Net margin (1,193.87%) (34,866.67%) (14.45%)
Free cash flow margin (866.56%) (30,198.96%) (3.88%)
Return on equity 364.89% (49.73%) (10.35%)
Return on assets (167.51%) (35.59%) (17.26%)
Return on invested capital (3,096.53%) (278.58%) (5.27%)

Growth

Metric LUCD SERA Medical Devices median
Revenue growth (TTM) 24.89% 1.05% 10.41%
EPS growth (last fiscal year) 34.29% 32.32% 28.17%
Revenue growth, 5-year CAGR — 26.51% 15.74%
Net income growth, 5-year CAGR 0.00% 0.00% 0.00%

Health

Metric LUCD SERA Medical Devices median
Debt to equity 2.15 0.00 0.04
Current ratio 1.33 1.88 2.74
Net debt to EBITDA 0.22 1.10 0.54

Dividend

Metric LUCD SERA Medical Devices median
Dividend yield — — 1.02%
Payout ratio — — 0.37

Size

Metric LUCD SERA Medical Devices median
Market cap 79.28m 82.05m 239.53m

Compare with another peer

Any metric, up to five companies and an Excel export Powerpack